论文部分内容阅读
目的评估马来酸曲美布汀治疗肠易激综合征(IBS)的疗效和安全性.方法采用前瞻性临床研究,予符合罗马Ⅲ标准的62例IBS患者口服马来酸曲美布汀4周。研究包括2周基线期,2周治疗期,4周治疗期和随后的2周随访期。治疗前后分别记录症状并检查肝、肾功能。结果62例IBS患者治疗4周后,总改善率为81.2%,IBS的主要症状明显改善。研究期间未发生明显不良反应。结论马来酸曲美布汀治疗IBS安全有效,值得临床推广。
Objective To evaluate the efficacy and safety of trimebutine maleate in the treatment of irritable bowel syndrome (IBS) .Methods A prospective clinical study was conducted to evaluate the efficacy and safety of trimebutine maleate in patients with IBS week. The study included a baseline of 2 weeks, a 2 week treatment period, a 4 week treatment period, and a subsequent 2 week follow-up period. Before and after treatment were recorded symptoms and check the liver and kidney function. Results After 62 weeks of treatment, the overall improvement rate was 81.2% in IBS patients. The main symptoms of IBS were significantly improved. No significant adverse reactions occurred during the study. Conclusion trimebutine maleate in the treatment of IBS safe and effective, worthy of clinical promotion.